To identify predictors associated with acute hematologic toxicity (HT) in cervical cancer treated with postoperative intensity-modulated radiotherapy (IMRT) and concurrent weekly nedaplatin. Materials/Methods: From August 2012 to October 2014, 40 patients with cervical cancer after radical surgery were treated at our institution with IMRT and concurrent weekly nedaplatin. The pelvic bone marrow (PBM) was delineated retrospectively on the initial planning CT images for each patient and divided into three subsites: Ilium, lower pelvis, and lumbosacral spine. The volume of each region receiving dose exceeding 10, 20, 30, 40, and 45 Gy (V10, V20, V30, V40, and V45, respectively) was recalculated and a dose-volume histogram was generated based on the original treatment plan. Hematologic toxicity was graded according to the RTOG acute radiation morbidity scoring criteria. Variables potentially predicting HT were included and analyzed. Endpoints included white blood cell count, absolute neutrophil count, hemoglobin, and platelet count nadirs. Multivariate regression models were used to test associations between parameters and HT. Results: Age, BMI, performance status, clinical stage, fractionated dose, and duration of chemoradiotherapy (CCRT) were not significantly correlated with HT (p>0.05). On multivariate regression analysis, the volume of PBM receiving doses greater than 10 Gy and 20 Gy (PBM-V10 and PBM-V20, respectively) were risk factors associated with grade 2 or worse HT (HT2+) (ORZ1.838; 95% CIZ1.198-2.821; pZ0.005; and ORZ1.351; 95% CIZ1.085-1.681; pZ0.007, respectively). If PBM-V10 exceeded 90%, the risk for developing! grade 2 leucopenia and neutropenia increased by factors of 5.92 and 6.0, respectively. Patients with PBM-V20 !75% had higher rates of !grade 2 neutropenia than those with PBM-V20<75% (15.0% vs. 47.5%, p<0.001). No correlations were observed between HT and V30/V40/V45. Dosimetric parameters for the lower pelvis and lumbosacral spine had stronger associations with HT, compared with those for the ilium. Cycles of chemotherapy and nedaplatin total dose were associated with WBC nadirs. Weekly dose of nedaplatin mainly affected hemoglobin content. The content of hemoglobin and platelet count nadirs decreased with the increase of the irradiated volume, but no significant correlations were observed between the two hematologic parameters and the dosimetric parameters for each portion of the pelvis bone marrow. There was a significantly negative correlation between platelet count nadirs and the total radiation dose (bZ-0.402, pZ0.01). Conclusion: PBM-V10 and PBM-V20 are associated with HT for cervical cancer patients undergoing CCRT. Total radiation dose, cycles of concurrent chemotherapy, and total and weekly dose of nedaplatin affect some of the HT parameters in various degrees.